Pharmaceutical Standards in Israel and EU Equivalents
Recommendation
25-28 August 2026
Copenhagen, Denmark
including 8 Interactive Workshops
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The European Parliament accepted the so called ACAA agreement between the European Union and Israel on October 23, 2012. This agreement which had been prepared some time ago has been now finalized.
Acccording to a press release: "The ACAA agreement (Agreements on Conformity Assessment and Acceptance of industrial products) with Israel is a framework agreement that recognizes Israel industrial standards as equivalents to European standards. An appendix regarding pharmaceutical products was added to the vote. The meaning of this is that the European Union will recognize the Israeli pharmaceutical standard, and Israeli pharmaceutical products can now be marketed without delay or further inspection (in parallel to similar marketing of European drugs in Israel). Additional appendixes covering other industrial spheres will be added to the framework agreement in the near future."
Source: Press Release EurActiv
Related GMP News
17.08.2026Why Root Cause Analysis is the Key to efficient CAPA
17.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan
17.08.2026FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites
12.08.2026When Training Fails: FDA Warning Letters Highlight GMP Training Deficiencies in 2026
29.07.2026EU-GMP for Veterinary Medicinal Products: What will change in Switzerland?
15.07.2026Root Cause Analysis and CAPA: Two more Warning Letters issued to Companies in Europe